Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung | Zendy

Sae Wada | Zendy; Nobukazu Fujimoto | Zendy; Kenichi Gemba | Zendy; Michiko Asano | Zendy; Yasuko Fuchimoto | Zendy; Katsuichiro Ono | Zendy; Shinji Ozaki | Zendy; Takumi Kishimoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung

Author(s) -

Sae Wada,

Nobukazu Fujimoto,

Kenichi Gemba,

Michiko Asano,

Yasuko Fuchimoto,

Katsuichiro Ono,

Shinji Ozaki,

Takumi Kishimoto

Publication year - 2012

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2012/821280

Subject(s) - pemetrexed , carboplatin , bevacizumab , medicine , adenocarcinoma , lung cancer , oncology , platinum , chemotherapy , cancer , biology , cisplatin , biochemistry , catalysis

We present two cases of relapsed adenocarcinoma of the lung: a 50-year-old male and a 67-year-old male. Both patients had previously been treated with platinum-containing systemic chemotherapy. In both cases, significant clinical efficacy was demonstrated with combination chemotherapy consisting of pemetrexed, carboplatin, and bevacizumab as salvage treatment. Adverse events were mild. This regimen might be a viable therapeutic option even after heavy treatment such as platinum-containing chemotherapy, especially for patients with preserved organ function and good performance status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research